Overview
- India’s CGM market is accelerating, with sales surging and a projection of $672.9 million by 2033 at a 19.1% annual growth rate, driven in part by wellness use.
- U.S. regulators cleared some monitors for over-the-counter sale in 2024, lowering access barriers as typical two‑week sensors retail near $50 in some markets but exceed $100 elsewhere.
- Researchers report no agreed standard for interpreting CGM data in healthy people, with clinicians often disagreeing and studies suggesting current “normal” ranges may not map cleanly to CGM patterns.
- Doctors caution that natural post‑meal glucose rises and a 5–15 minute sensor lag are frequently misread, fueling anxiety, obsessive tracking and restrictive eating promoted by influencer content.
- Clinicians emphasize CGMs’ proven value for insulin‑treated diabetes and hypoglycemia risk, and recommend established tests like OGTT and HbA1c for risk assessment in people without diabetes.